

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

**Complete if Known**

Attorney Docket Number	80657(47762)
------------------------	--------------

Sheet	1	of	2
-------	---	----	---

[illegible]

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	† <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	BA	JP-09-255659	09-30-1997	Dainippon Ink & Chemicals	abstract only	

Examiner Signature	/Chris Simmons/	Date Considered	11/10/2008
--------------------	-----------------	-----------------	------------

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(ii)) because that application was filed after June 30, 2003 or is available in the IFW. Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.S./

PTO/SB/08b (01-08)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/565,828-Conf. #7933
				Filing Date	January 25, 2006
				First Named Inventor	Hidetsugu Takagaki
				Art Unit	1614
				Examiner Name	C. E. Simmons
Sheet	2	of	2	Attorney Docket Number	80657(47762)

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/C.S./	CA	Yasuo Aoki et al., "Inhibitory effect of a novel quinolinone derivative, TA-270, on asthmatic inflammatory responses in sensitized guinea pigs," European Journal of Pharmacology 409(2000) pp. 325-330.	
/C.S./	CB	Masakazu Ichinose et al., "Increase in Reactive Nitrogen Species Production in Chronic Obstructive Pulmonary Disease Airways," Am J Respir Crit Care Med, Vol 162, pp. 701-706, 2000.	
/C.S./	CC	Brain J. Dykstra et al., "Lung Volumes in 4,774 Patients with Obstructive Lung Disease," CHEST 1999, 115, pp. 68-74.	
/C.S./	CD	Peter Thomas et al., "Theophylline and Salbutamol Improve Pulmonary Function in Patients with Irreversible Chronic Obstructive Pulmonary Disease," CHEST 1999, 115, pp.160-165.	
	CE	<del>The English translation for Y. Yoshimura et al., "Hot to Use Steroid Drugs" ("Steroid-yaku no Tsukikata,") Medicine, vol. 80, No. 12, 1999, pp. 2148-2149.</del>	
/C.S./	CF	"Global Initiative for Chronic Obstructive Lung Disease," Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, Updated 2005 (55 sheets).	

Examiner Signature	/Chris Simmons/	Date Considered	11/10/2008
--------------------	-----------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

DOCUMENT CE is crossed out because the title of the submitted document does not contain the term "Hot"; however, the title on the IDS does